Albany Molecular Research (AMRI) Misses Q4 EPS by 14c; Guides Below the Street
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
AMRI Announces Fourth Quarter and Full Year 2016 Results and Provides 2017 Outlook
February 21, 2017 7:28 AM ESTALBANY, N.Y., Feb. 21, 2017 /PRNewswire/ --Â AMRI (NASDAQ: AMRI) today reported financial and operating results for the fourth quarter and full year ended December 31, 2016 and provided an outlook for 2017.
Highlights:
Fourth quarter total revenue of $191.3 million, up 51% from 2015 Full year total revenue of $570.5 million, up 42% from 2015 Fourth quarter reported basic and diluted EPS $(0.37); non-GAAP diluted EPS of $0.34 Full year reported basic and diluted EPS $(1.83); non-GAAP diluted EPS of $0.95 Fourth quarter reported net loss of $15.4 million; non-GAAP net income of $14.8 million... More